Background: Activation of the Notch pathway has been reported in various types of cancers. However, the role of the hairy/ enhancer-of-split related with YRPW motif protein 1 (HEY1) in osteosarcoma is unknown. We examined the function of HEY1 in osteosarcoma.
release of the Notch intracellular domain and subsequent translocation to the nucleus (Kopan and Ilagan, 2009 ). The Notch intracellular domain forms a transcriptional activation complex with RBPJ transcription factors (CBF1/RBP-Jk, Su(H), Lag-1) and converts them from repressors to activators, promoting transcription of the target genes involved in various developmental and differentiation processes (Koch et al, 2013) . Aberrant activation of Notch signalling also has a role in various types of malignant tumour pathogenesis (Shao et al, 2012) . We previously reported that Notch signalling was activated in human osteosarcoma and inhibition of Notch signalling prevented osteosarcoma growth in vitro and in vivo (Tanaka et al, 2009) . In this report, we examined the role of hairy/enhancer-of-split related with YRPW motif protein 1 (HEY1), a transcription factor regulated by the Notch pathway, in human osteosarcoma. We found that expression of HEY1 is upregulated in human osteosarcoma. In addition, HEY1 promoted osteosarcoma cell invasion and lung metastasis via upregulation of MMP9.
MATERIALS AND METHODS
Cell lines and reagents. Osteosarcoma cell lines 143B, HOS, Saos-2, U2OS and MG-63 were received from the American Type Culture Collection (ATCC, Manassas, VA, USA). NOS-1 and HSOs-1 cell lines were obtained from the Riken Bioresource Center (Tsukuba, Japan). Cell lines were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% foetal bovine serum (FBS), 100 U ml À 1 penicillin, and 100 mg ml À 1 streptomycin. Hu-09, HuO-3N1 and NY cell lines were obtained from the Health Science Research Resources Bank (HSRRB; Osaka, Japan). Cell lines were cultured in Roswell Park Memorial Institute 1640 medium supplemented with 10% FBS. Normal human osteoblast cells (NHOst; Sanko Junyaku, Tokyo, Japan) were grown in OBMTM medium (Cambrex, East Rutherford, NJ, USA). A human bone marrow-derived mesenchymal stem cell (MSC) line, UBE6T15, was purchased from HSRRB. UBE6T15 cells were grown in DMEM with 10% FBS.
Real-time PCR. For real-time polymerase chain reaction (PCR), total RNA from osteosarcoma cell lines and HEY1 siRNAtransfected osteosarcoma cells were isolated by using TRIzol (Invitrogen, Carlsbad, CA, USA) and purified by using the mirVana miRNA isolation kit (Invitrogen). Reactions were run using SYBR Green (BIO-RAD, Hercules, CA, USA). The comparative Ct (DDCt) method was performed to determine the fold-change of mRNA expression using actin-beta (ACTB) as a reference. Each sample was run in triplicate. The primer sequences used were as follows: HEY1: Expression vector. The pCMV6-Entry vector (PS100001) and HEY1 expression vector (RC200257) were purchased from OriGene Technologies (Rockville, MD, USA). All plasmids were transfected into UBE6T15 cells by using electroporation (Amaxa Nucleofector; Lonza, Tokyo, Japan).
Cell proliferation assay. We seeded 5 Â 10 2 cells per 100 ml in a 96-well plate. Cell growth was measured daily using the WST-1 cell proliferation assay (Roche, Basel, Switzerland).
Invasion assay. Invasive activity was measured using BD Matrigel (BD Bioscience, Franklin Lakes, NJ, USA) according to the manufacturer's protocol. Briefly, transfected osteosarcoma cells in 2 ml of serumfree medium were seeded into the upper chamber of the system. The bottom wells in the system were filled with DMEM and 10% FBS. After incubation (16-24 h), the cells in the upper chamber were removed, and the cells on the bottom membrane were stained. The cells that invaded were counted in five random fields of the membrane. The invasion efficiency of the control cells was estimated as 100%. To confirm whether HEY1 induce a cell invasion, we performed an invasion assay which equalises the number of each osteosarcoma cell line. To determine whether MMP9 rescued the decrease in the invasive activity, we added the recombinant active human MMP9 (Sino Biological Inc., Peking, China) to the upper chamber.
Western blot. Cells were lysed by using NP40 lysis buffer (0.5% NP40, 10 mM Tris-HCl (pH 7.4), 150 mM NaCl, 3 mM pAPMSF (Wako Chemicals, Kanagawa, Japan), 5 mg ml À 1 aprotinin (Sigma, St. Louis, MO, USA), 2 mM sodium orthovanadate (Wako Chemicals) and 5 mM EDTA. Lysates were subjected to SDS-PAGE followed by immunoblotting. The following antibodies were used: anti-HEY1 (1 : 200, ab22614, Abcam, Cambridge, UK; Figure 1B , Supplementary Figure 2B ), anti HEY1 (1 : 200, H00023462-M01, Abnova, Taipei, Taiwan; Figure 3 ) and b-tubulin (1 : 1000, DM1A, Sigma-Aldrich Co. LLC). Detection was performed by using the enhanced chemiluminescence detection system (Amersham, Giles, UK).
Gene infection for in vivo examination. Cells were infected with control shRNA lentiviral particles (sc-108080), HEY1 shRNA lentiviral particles (sc-37914-V) or copGFP control lentiviral particles (sc-108084). All lentiviral particles were purchased from Santa Cruz Biotechnology. Infected cells were selected in 1 mg ml À 1 neomycin or 1-2 g ml À 1 puromycin.
Animal studies of osteosarcoma lung metastasis. For metastasis experiments, 143B cells (5 Â 10 5 ) were transfected with GFP lentiviral particles (Santa Cruz), as previously reported (Matsunoshita et al, 2011; Nagao-Kitamoto et al, 2014) . Briefly, control or HEY1 shRNA-transfected 143B cells (control shRNA/ 143B and HEY1 shRNA/143B, respectively) were infected with GFP lentiviral particles. Stably GFP-expressing 143B cells (1 Â 10 6 ) were suspended in 100 ml of Matrigel (BD Biosciences). Cell suspensions were inoculated into the left-knee joint of 5-week-old nude mice (Japan SLC, Inc., Hamamatsu, Japan). Mice were sacrificed 7.5 weeks. Lung metastases were evaluated by using fluorescence microscopy (Leica Microsystems AG, Heerbrugg, Switzerland). All animal experiments were performed in compliance with the guidelines of and were accepted by the Animal Science Laboratory, Frontier Science Research Center, Kagoshima University. All efforts were made to minimise animal suffering, to reduce the number of animals used and to utilise possible alternatives to in vivo techniques.
ELISA assay. Expression levels of MMP9 protein were assayed using specific enzyme-linked immunosorbent assay kits according to the manufacturer's instructions (Abcam).
Patient specimens. All human osteosarcoma biopsy specimens were obtained from primary lesions. Biopsies were performed before chemotherapy and used for diagnostic purposes. Normal bone tissue was obtained from the femur during total hip arthroplasty. The Institutional Review Board of Kagoshima University accepted the study protocol. All patients and control subjects gave written informed consent to participate in the study.
Statistical analysis. Statistical analyses were performed using the Student's t-test with Microsoft Office Excel (Microsoft, Albuquerque, NM, USA). The Mann-Whitney U test was conducted by Souken Co., Inc. (Tokyo, Japan). Spearman's rank correlation coefficient was performed with Excel Statistics 2012 (SSRI, Tokyo, Japan). P-values o0.05 were considered statistically significant.
RESULTS
HEY1 and HEY2 are upregulated in human osteosarcoma cell lines. We previously reported that Notch-related genes were upregulated in human osteosarcoma specimens (Tanaka et al, 2009) . We focused on HEY1 and HEY2 because their function in human osteosarcoma is not well understood. Real-time PCR showed that many human osteosarcoma cell lines elevated HEY1 and HEY2 ( Figure 1A) , and that 8 out of 10 human osteosarcoma biopsy specimens had showed an increased HEY1 and HEY2 expression compared with normal bone (Tanaka et al, 2009) . Western blot analysis revealed that HEY1 protein levels were elevated in osteosarcoma cell lines compared with NHost (normal osteoblast) ( Figure 1B) .
Knockdown of HEY1 prevents osteosarcoma invasion but not proliferation. To examine the function of HEY1 and HEY2 in human osteosarcoma, we examined cell proliferation by using the WST-1 assay. Knockdown of HEY1 by siRNA (sc-37913: Santa Cruz Biotechnology) decreased the expression of HEY1 mRNA and protein (Figure 2 and Supplementary Figure 1A , B). Knockdown of HEY1 or HEY2 did not affect the proliferation of human osteosarcoma cells (Supplementary Figure 1B) . The cell invasion assay showed that the knockdown of HEY1 prevented 143B osteosarcoma cell invasion (Figure 2A ). To rule out the possibility of off-target effects, we examined an alternative HEY1-specific siRNA (LQ-008709-00-0002: Thermo Fisher Scientific) which also inhibited invasion (Supplementary Figure 2A) . In addition, knockdown of HEY1 prevented HS-Os-1 and MG63 osteosarcoma cell invasion ( Figure 2B and C). Knockdown of HEY2, however, did not affect the invasion of osteosarcoma cells (data not shown).
HEY1 promotes invasion of osteosarcoma and MSCs. We examined the effect of forced expression of HEY1 on invasion. Because osteosarcoma is thought to originate from MSCs (27), we used UBE6T15, a human MSC line, to examine the role of HEY1 in invasion. UBE6T15 cells transfected with the HEY1 expression vector showed upregulated HEY1 protein levels ( Figure 3A) . Invasion of HEY1-transfected UBE6T15 cells was greater than that of control vector-transfected cells ( Figure 3B ). We examined the correlation between expression of HEY1 and invasion of osteosarcoma cell lines. RT-PCR and invasion assays showed that osteosarcoma cells with high expression of HEY exhibited increased invasive activity ( Figure 3C ).
Knockdown of HEY1 prevents lung metastasis of osteosarcoma cells. We evaluated the role of HEY1 in lung metastasis in a mouse xenograft model. Knockdown of HEY1 did not affect the growth of original site osteosarcoma in knee joints (data not shown). The percentage and number of lung metastases in mice inoculated with HEY1 shRNA/143B-GFP was significantly less than in control mice inoculated with shRNA/143B-GFP ( Figures 4A and B) . In addition, the area of lung metastasis in mice inoculated with HEY1 shRNA/143B-GFP was significantly smaller than in control mice inoculated with shRNA/143B-GFP ( Figure 4C ). These findings suggest that knockdown of HEY1 inhibits osteosarcoma lung metastasis.
MMP9 acts downstream of HEY1 to regulate invasion of osteosarcoma. To gain further insight underlying HEY1-mediated invasion of osteosarcoma, we selected genes that were reported to regulate invasion of cancer cells. RT-PCR revealed that MMP9 was decreased using knockdown of HEY1 in osteosarcoma cells ( Figure 5 and Supplementary Figure 3A) . The ELISA assay showed that knockdown of HEY1 decreased the expression of MMP9 protein ( Figure 6A ). The number of invasive cells was decreased in HEY1 shRNA cells; however, this phenotype was largely reversed by the addition of active MMP9 protein ( Figure 6B ). These findings suggest that HEY1 promotes osteosarcoma cell invasion via expression of MMP9.
Strong correlation between HEY1 and MMP9 expression. To validate whether HEY1 expression was correlated with MMP9 expression, we measured the expression of MMP9 protein in osteosarcoma cell line by ELISA assay. We found that the expression of HEY1 correlated with MMP9 protein (Figure 7 ). At last, we examined the expression of MMP9 in osteosarcoma patient specimens. RT-PCR revealed that MMP9 was overexpressed in osteosarcoma specimens (Supplementary Figure 3B) .
DISCUSSION
Although dysregulated Notch pathway is an attractive target to treat cancers, it is possible that the inhibition of Notch pathway by g-secretase inhibitors, Notch antisense and or anti-Notch monoclonal antibodies could result in toxicity of normal stem cells, gastrointestinal toxicity, diarrhoea, hepatotoxicity and nephrotoxicity (Searfoss et al, 2003; van Es et al, 2005; Garber, 2007; Wu et al, 2010; Purow, 2012) . Given the potential toxicity, specifically targeting a Notch target gene instead might provide greater clinical benefit. We showed that knockdown of HEY1 prevented osteosarcoma invasion and lung metastasis. These findings suggest that targeting HEY1 may be a better way to prevent osteosarcoma HEY1 shRNA HEY1 shRNA ***P < 0.001 Figure 4 . Knockdown of HEY1 prevents osteosarcoma cells from metastasising to the lung. Stably GFP-expressing control shRNA/143B or HEY1 shRNA/143B cells were inoculated into the left knee joint of nude mice (n ¼ 7 for control, n ¼ 6 for HEY1 shRNA group). Seven and a half weeks post inoculation, the mice were sacrificed. Lung metastases were evaluated by using fluorescence microscopy, and the number of metastatic tumours was calculated by using Image J software. Photographs show lung metastases for each group. Knockdown of HEY1 decreased the percentage of mice with lung metastases (A), the number of lung metastases (B), and the area of lung metastases (C). *Po0.05, **Po0.01, Mann-Whitney U test and Student's t-test.
metastasis and provide greater clinical benefit than Notch inhibitors. Expression of HEY1 is regulated by Notch signalling (Maier and Gessler, 2000; Nakagawa et al, 2000) . In addition, bone morphogenetic proteins (BMPs) and transforming growth factor beta (TGF-b) increase the expression of HEY1 (de Jong et al, 2004; Zavadil et al, 2004) . It has been reported that BMPs and TGF-b regulate osteosarcoma cell motility and lung metastasis (Sotobori et al, 2006; Weiss et al, 2006; Zhang et al, 2013) . Our findings suggest that inhibition of HEY1 may prevent osteosarcoma invasion and lung metastasis caused by not only the Notch pathway but also by BMPs and TGF-b activation.
Although HEY1 is involved in the development of the heart, neurogenesis and osteogenesis (Sakamoto et al, 2003; Kokubo et al, 2005 Kokubo et al, , 2007 Sharff et al, 2009; Salie et al, 2010) , it has been reported that HEY1 over-expression was a negative prognostic factor for several cancers (Hulleman et al, 2009; Mann et al, 2012; Candy et al, 2013) . Our findings also suggest that over-expression of HEY1 may increase lung metastasis, which worsens the prognosis. Further studies using clinical samples are needed to examine the association of HEY1 expression with prognosis.
MMPs are involved in the degradation of the extracellular matrix. MMP2 and MMP9 are the most consistently overexpressed in malignant tumours and are associated with aggressiveness, metastatic potential and poor prognosis (Hidalgo and Eckhardt, 2001 ). HEY1 expression is regulated by many signalling molecules including CD147, the PI3K/AKT pathway, epidermal growth factor receptor and fibroblast growth factor 11 (Toole, 2003; Hu et al, 2014; Wang et al, 2014; Zhang et al, 2014) . We showed that MMP9 was upregulated in human osteosarcoma specimens and cell lines as previously reported (Kawashima et al, 1994; Cho et al, 2007; Xin et al, 2009) invasion of human cancers (Wang et al, 2006; Bin Hafeez et al, 2009; Gao et al, 2012) . Cancers and neural stem cells that express HEY1 acquire high invasive potential (Bolos et al, 2013; Sailer et al, 2013) . Our findings suggest that Notch-regulated cell invasion and MMP9 expression mediated by HEY1 occurs not only in osteosarcoma but also in other cancers as well as endothelial cells in rheumatoid arthritis. Although we showed that HEY1 regulates the expression of MMP9, we have not yet defined whether MMP9 is a direct transcriptional target of HEY1. Villaronga et al (2010) reported that HEY1-L94M, with a single nucleotide polymorphism, behaves as a potent transcriptional co-activator of the androgen receptor. Heisig et al (2012) reported that HEY proteins primarily act as direct transcriptional repressors, whereas their role in gene activation appears to be because of secondary or indirect effects. Consistent with these findings, results from our chip assay revealed that HEY1 did not bind to the MMP9 promoter (data not shown). Additional studies will be necessary to determine which factor or HEY1 gene variant mediates the expression of MMP9 related to HEY1 expression.
In conclusion, we found new clues associating HEY1 with osteosarcoma metastasis, which opens up the possibility of targeted inhibition of HEY1 for the treatment of osteosarcoma metastasis. We examined the expression of HEY1 and MMP9. HEY1 and MMP9 mRNA expression was examined by using NHost (normal osteoblast), UBE6T15 (mesenchymal stem cell), and eight human osteosarcoma cell lines. Spearman's rank correlation coefficient test showed that correlation between HEY1 and MMP9 expression was significant. The experiment was performed in triplicate with similar results. Po0.01.
